Laboratorio Reig Jofre (LTS:0RB1) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RB1 Laboratorio Reig Jofre SA LTS:0RB1
81 GF Score
Price €2.65
GF Value €2.73
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Laboratorio Reig Jofre FFO per Share?

FFO per Share only applies to REITs.

LTS:0RB1
81GF Score
Laboratorio Reig Jofre SA LTS:0RB1
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Laboratorio Reig Jofre (LTS:0RB1) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued. The current stock price of €2.65 is trading 2.9% below its estimated GF Value™ of €2.73. GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.

Key valuation signals for LTS:0RB1:

  • FFO per Share:
  • GF Value™: €2.73 vs. price of €2.65 (2.9% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the LTS:0RB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorio Reig Jofre Business Description

Other Exchanges RJF:SpainFEQ1:Germany
Address Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
81GF Score

Get the complete analysis for LTS:0RB1

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.65
Price
€2.73
GF Value